Main uses of Benepali

Benepali is a biologic medicine used to treat several chronic inflammatory conditions. It contains the active substance etanercept, which works by targeting and neutralizing a specific protein in the body called tumor necrosis factor (TNF). In healthy individuals, TNF helps regulate the immune response, but in people with certain inflammatory diseases, the body produces too much of it, leading to pain, swelling, and tissue damage.

Rheumatoid arthritis

Benepali is used for the treatment of moderate to severe active rheumatoid arthritis in adults. It is typically prescribed when other medicines, such as methotrexate, have not worked well enough or are not suitable. It can be used on its own or in combination with methotrexate to reduce symptoms and slow down the progression of joint damage.

Psoriatic arthritis

For adults with active and progressive psoriatic arthritis, Benepali is used to improve physical function and reduce the inflammation of the joints and skin. It is generally used when the response to previous disease-modifying therapies has been inadequate.

Axial spondyloarthritis

Benepali is used to treat adults with severe inflammatory diseases of the spine, including:

• Ankylosing spondylitis: A chronic condition causing inflammation of the joints in the spine.
• Non-radiographic axial spondyloarthritis: A condition where the patient has clear symptoms of spinal inflammation, but the damage is not yet visible on X-rays.

Plaque psoriasis

In cases of moderate to severe plaque psoriasis, Benepali is used for adults who have not responded to, or who cannot use, other systemic therapies such as cyclosporine or methotrexate. It helps clear the skin and reduce the redness, scaling, and thickness of psoriatic plaques.

Pediatric use

Benepali is also used for specific conditions in children and adolescents:

• Juvenile idiopathic arthritis: Treatment for polyarthritis and extended oligoarthritis in children from the age of 2 years, as well as psoriatic arthritis and enthesitis-related arthritis.
• Paediatric plaque psoriasis: Treatment for severe chronic plaque psoriasis in children and adolescents from the age of 6 years.

Benefits and expectations

The primary goal of treatment with Benepali is to control inflammation and improve the patient's quality of life. By blocking the action of excess TNF, the medicine can help achieve the following:

• Reduction in symptoms: Decrease in joint pain, stiffness, and swelling.
• Improved physical function: Enhancement of the ability to perform daily activities and movements.
• Skin clearance: Significant reduction in the extent and severity of skin lesions in patients with psoriasis.
• Prevention of damage: Slowing the progression of structural damage to bones and cartilage in the joints.

Regulatory References

1. European Medicines Agency (EMA) Benepali EPAR

Benepali must not be used in specific patient populations, which are defined by formal contraindications in the official regulatory label. These exclusions include patients who have sepsis or are at risk of sepsis, have any active infection (including chronic or localised infections), or have a confirmed hypersensitivity to the active substance, Etanercept, or any excipients.

---

Official Eligibility Status

Classification	Population/Condition	Restriction/Requirement
Permitted Use	Adults (ge 18 years)	No dose adjustment for elderly, renal, or hepatic impairment.
Contraindicated	Active Infection/Sepsis	Must not be initiated.
Conditional Use	Latent Tuberculosis (TB)	Anti-TB therapy must be started before initiation.
Conditional Use	Congestive Heart Failure (CHF)	Use requires caution and monitoring.
Not Recommended	Pregnancy/Breastfeeding	Use is not recommended during lactation. Contraception is required during treatment and for three weeks after.
Not Indicated	Pediatric Population	Not indicated for children who weigh less than 62.5 kg due to formulation limitations.

---

Use is also not recommended in combination with biologic medicines like anakinra or abatacept. Caution is also required in patients with a history of demyelinating disorders or a history of Hepatitis B Virus (HBV) infection, who must be tested and monitored.

Interactions with other medicines and products

The official interaction profile for Benepali, which contains the active substance etanercept, is based on documented pharmacodynamic interactions with other medicinal products and vaccines.

Combinations Not Recommended:

• Anakinra: Concurrent administration of Benepali with the interleukin-1 receptor antagonist Anakinra is not recommended. This combination has been associated with a higher incidence of serious infections and neutropenia without demonstrating increased clinical benefit.
• Abatacept: The combination of Benepali with the selective T-cell co-stimulation modulator Abatacept resulted in increased incidences of serious adverse events in clinical studies; therefore, this co-administration is not recommended.
• Live Vaccines: The administration of live vaccines concurrently with Benepali should be avoided. Benepali may affect the body’s ability to respond to vaccinations, and there is a potential for transmitting the infectious agent from the vaccine.

Products Requiring Monitoring or Adjustment:

• Anti-diabetic medicines: Patients who are also taking anti-diabetic medicines should be monitored. An adjustment to the dose of the anti-diabetic medicine may be necessary while the patient is receiving treatment with Benepali.

How Benepali Works

Neutralizing the TNF-alpha Signal

Benepali functions as a decoy receptor, circulating in the body and binding directly to the inflammatory signaling protein Tumor Necrosis Factor alpha ( TNF-alpha). This binding action effectively neutralizes the protein. The mechanism prevents the TNF-alpha from attaching to its cognate receptors on immune cells, which directly inhibits the transmission of the inflammatory signal.

Interrupting the Inflammatory Cascade

By blocking the TNF-alpha signal input, the drug interrupts the entire intracellular inflammatory signaling cascade. This suppression prevents the downstream release of numerous other pro-inflammatory chemical messengers. This activity results in a decrease in molecular markers associated with processes of inflammation.

Resulting Systemic Physiological Modulation

This targeted mechanism leads to a systemic modulation of immune and inflammatory pathways. The alteration affects pathway dynamics and contributes to adjustments in mediator activity within the immune system, shifting the physiological environment toward a more controlled state of immune signaling.

How to Use Benepali: Administration Instructions

Benepali is administered as an injection under the skin (subcutaneous injection) and should only be given by the patient or a trained caregiver after receiving proper instruction.

Dosing and Frequency Rules

Condition	Dose and Frequency
Adults (RA, PsA, AS, nr-axSpA)	50 mg once weekly
Adults (Plaque Psoriasis)	50 mg once weekly, OR 50 mg twice weekly for up to 12 weeks, followed by 50 mg once weekly

Administration Requirements

Procedural Element	Instruction
Route	Subcutaneous injection
Preparation	Allow the pre-filled pen or syringe to reach room temperature for at least 30 minutes before use. Do not warm it using external heat sources.
Visual Check	Inspect the solution; it should be clear to slightly opalescent, colourless to pale yellow, and may contain small white/transparent protein particles. Do not use if cloudy, discoloured, or if other particles are visible.
Site Rotation	Inject into a different spot on the abdomen or thigh each time. Do not inject into skin that is tender, bruised, red, or hard.
Missed Dose	If a dose is missed, inject it as soon as possible, and then return to the regular schedule for the next dose. Do not inject a double dose to make up for the missed one.
Pediatric Use	The 50 mg pre-filled format is not indicated for pediatric patients who require a dose other than a full 50 mg, such as those weighing less than 62.5 kg, as dosing for this age group is weight-based.

All treatment must be initiated and supervised by a physician specialist. These instructions describe the correct administration and scheduling of the medicine.

Research evidence / Overview of studies for Benepali

The research foundation for Benepali in rheumatoid arthritis (RA) includes dedicated short-term, double-blind clinical trials. These studies were designed to investigate the similarity of Benepali to its reference medicine in adults with moderate to severe active RA. Researchers monitored key clinical measurements, such as standardized disease activity scores (e.g., ACR and DAS28), which was studied for outcomes related to physical discomfort. The primary head-to-head trials reported these measurements over the short-term study period, with extended monitoring up to 52 weeks in some open-label extensions.

---

Evidence for use in Psoriatic Arthritis (PsA) and Plaque Psoriasis (PsO)

The evidence informing the use of Benepali for Psoriatic Arthritis and Plaque Psoriasis relied primarily on the scientific principle of extrapolation. This means research exploring similarity in RA was evaluated for application to these other conditions. Dedicated large-scale, randomized trials were not conducted for PsA and PsO; instead, the evidence is supplemented by real-world observational studies tracking patient outcomes related to physical discomfort and daily functioning.

---

Key Research Gaps and Structural Uncertainties

The evidence base is based on studies intended to establish biosimilarity in RA. Long-term effects are not fully established specifically for Benepali beyond the periods documented in the core studies, although observational studies track drug retention for one year or longer. The reliance on therapeutic extrapolation for PsA and PsO means that certainty remains low compared to the core RA indication. Furthermore, data for children and pregnant populations for this specific formulation remain insufficient.

Common questions about Benepali (FAQ)

Q: Is Benepali the same as the reference medicine Enbrel?

Benepali is officially classified as a biosimilar medicine to the reference product, Enbrel (etanercept). A biosimilar is a biological medicine that is highly similar to the original product in terms of structure and quality. Regulatory authorities have determined there are no clinically meaningful differences between them regarding safety or effectiveness.

Q: Why are some people being switched from Enbrel to Benepali?

Switching from the reference product to a biosimilar like Benepali is often a decision made at the health system or institutional level. The use of an approved biosimilar is supported by regulatory evidence that it provides a comparable therapeutic option. This kind of transition is not expected to affect the efficacy or safety of the treatment.

Q: How long does it usually take to feel the effects of Benepali?

Official information does not guarantee a specific time frame for when a person will feel the effects. The clinical studies used to evaluate the drug's effectiveness typically measure significant improvements over periods of around 24 weeks. Individual responses may vary. Questions regarding expected timeline of effect are best addressed by a healthcare professional.

Q: What should I do if I experience a severe allergic reaction to Benepali?

If a severe allergic reaction, such as anaphylaxis, is suspected, official instructions indicate that the injection should be immediately stopped and urgent medical attention sought. Regulatory documents list hypersensitivity to the drug as a contraindication, meaning it should not be used if a patient has a known allergy.

Q: Is it safe to get vaccines, such as a flu shot, while on Benepali?

It is advised that patients avoid receiving live vaccines while on this medication, as it can affect the immune system's response. However, most common vaccines, like the seasonal flu shot, are typically inactivated (non-live) and are generally considered permissible. Consultation with a healthcare provider regarding all planned vaccinations is essential.

Q: Can I take Benepali if I have a history of heart problems or heart failure?

Official information advises that caution is needed when using Benepali in patients who have Congestive Heart Failure (CHF). Studies involving the active substance were stopped in patients with pre-existing heart failure due to a trend toward worsened heart failure in some cases. Regulatory warnings indicate that the use of this medicine requires careful evaluation and monitoring by a physician.

Q: What are the concerns about taking Benepali if I have diabetes?

Patients with diabetes have a higher underlying risk of infection, which requires caution when using an immunomodulator. Additionally, there have been regulatory reports of hypoglycemia (low blood sugar) following the start of treatment in patients taking anti-diabetic medicines. This effect may result in the need for closer blood sugar monitoring or an adjustment to anti-diabetic medication by a physician.

Q: Can Benepali cause or worsen existing nervous system conditions?

Official safety warnings indicate caution in using this drug in people with pre-existing or recent-onset demyelinating disorders of the nervous system, such as multiple sclerosis. Rare cases of these disorders have been associated with the active substance, and regulatory information advises close monitoring of patients who develop new neurological symptoms.

Q: Do older patients (geriatric population) need a different Benepali dosage?

Regulatory data has not demonstrated a need for a specific dose adjustment for older adult patients; the standard dose is generally used. However, official information notes that older patients have a higher incidence of serious infections, which is a key safety consideration requiring careful monitoring.

Q: Can Benepali be used in children or adolescents?

Benepali is indicated for treating specific forms of Juvenile Idiopathic Arthritis (JIA) and pediatric plaque psoriasis. However, the 50 mg pre-filled pen format is typically not indicated for children who require a dose less than 50 mg (for example, those below a certain weight), as dosing for younger patients is weight-based.

Q: What are the results of research comparing Benepali's safety to the reference drug?

The research program confirmed a comparable overall safety profile when Benepali was studied against the reference product. Regulatory reviews concluded that Benepali is highly similar, and therefore the safety profile established for the reference product applies to Benepali.

Q: Are the Benepali pre-filled pens known to be painful to use?

Injection site pain is listed as a very common adverse reaction in the official product information. This discomfort is usually described as mild to moderate and tends to lessen over time. Official instructions advise allowing the pen to reach room temperature for at least 30 minutes before use, which may be associated with reduced injection site pain.

Q: What happens if I forget to take my Benepali injection?

Official instructions state that a missed dose may be administered as soon as it is remembered. The patient should then return to their regular scheduled day for the next dose. It is strictly advised to not inject a double dose to make up for the forgotten one.

Q: How is Benepali administered, and where are the injection sites?

Benepali is administered as an injection under the skin (subcutaneous injection) using the pre-filled pen or syringe. The injection sites should be rotated each time, and the recommended areas are the thigh or the abdomen.

Q: Is Benepali appropriate for all stages of rheumatoid arthritis?

The medicine is specifically indicated for the treatment of moderate to severe active rheumatoid arthritis in adults, especially when other treatments have not been sufficient. It is also indicated for patients with severe, active and progressive RA who have not been previously treated. It is not generally indicated for mild or inactive stages of the disease.

Q: Does Benepali interact with alcohol?

Official regulatory documents do not list a specific contraindication for the use of alcohol with Benepali. However, an uncommon side effect is the elevation of liver enzymes. Because alcohol can also affect the liver, questions regarding alcohol consumption are best addressed by a healthcare professional.

Q: Will I be able to drive or operate machinery while taking Benepali?

Official information does not contain any special warning regarding the ability to drive or operate machinery. Caution is advised if patients experience side effects like dizziness or visual disturbance, which could potentially impair judgment.

Q: Has Benepali been studied in patients with inflammatory bowel disease (IBD)?

Benepali is not indicated or approved for the treatment of Inflammatory Bowel Disease (IBD), which includes conditions like Crohn's disease or ulcerative colitis. Its licensed indications are limited to specific forms of arthritis and psoriasis.

Q: Is Benepali approved for treating non-radiographic axial spondyloarthritis?

Yes, Benepali is indicated for the treatment of adults with severe non-radiographic axial spondyloarthritis. This use is subject to the condition that the patient has objective signs of inflammation and has not responded adequately to standard nonsteroidal anti-inflammatory drugs (NSAIDs).

Q: Does Benepali contain any sodium or other inactive ingredients that I should know about?

Yes, the solution contains other inactive ingredients, or excipients, in addition to the active substance. Official assessment reports have noted the composition includes substances like sodium chloride and sodium phosphate, which are necessary to maintain the drug's stability and formulation.

Q: Is it true that Benepali can increase the risk of serious infections, like tuberculosis?

Yes. The risk of serious infections, including opportunistic infections such as tuberculosis, is an important safety consideration addressed by regulators. Patients are closely monitored for new infections, and regulatory guidelines require that screening for latent tuberculosis be conducted prior to the initiation of treatment.

Q: Is it true that Benepali can increase the risk of certain cancers?

Regulatory documents include warnings about the potential for malignancies (cancers), including lymphoma and non-melanoma skin cancers, reported in patients treated with the active substance. Questions regarding this potential risk are best addressed by a healthcare professional.

Q: What are the restrictions on using Benepali before and after surgery or dental work?

The drug is contraindicated (must not be used) in patients who have active infections or are at risk of sepsis. Regulatory information advises that the decision to temporarily stop treatment before or after procedures should be made in consultation with a physician, due to the potential risk of infection.

Storage and Disposal of Benepali (Etanercept)

Benepali requires strict adherence to labeled conditions for storage and disposal to ensure product stability, as documented in regulatory guidelines.

---

Official Storage Conditions

Benepali must be stored in a refrigerator at a temperature between 2 C and 8 C. It is mandatory to not freeze the medicine. The pre-filled pen or syringe must be kept in the original outer carton for protection from light. The product must be stored out of the sight and reach of children.

Stability and Handling

A single pen or syringe may be stored outside of refrigeration at a temperature up to a maximum of 30 C for a single period of up to 31 days. If this time limit is exceeded, the medicine must be discarded. Once removed from the refrigerator for this temporary storage, it must not be returned to the refrigerator.

Disposal Instructions

Used Benepali pens and syringes must be placed immediately in an approved sharps disposal container. The final disposal of the filled sharps container must follow all applicable local regulations. The medicine must not be disposed of in household trash or wastewater.